Alicia Clawson

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 614 citations

Medicine, Oncology, Pharmacology +12

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Eytan M. Stein, Guillermo Garcia‐Manero, David A. Rizzieri et al. · Blood · 2018 · 457 citations · Full text

Life Sciences, Molecular Biology, Oncology +10

Significantly Longer Progression-Free Survival With <i>nab</i>-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

William J. Gradishar, D. Krasnojon, Sergey Cheporov et al. · Journal of Clinical Oncology · 2009 · 343 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes

Joanne L. Blum, Michael A. Savin, Gerald M. Edelman et al. · Clinical Breast Cancer · 2007 · 178 citations

Medicine, Oncology, Pharmacology +16

Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival

William J. Gradishar, D. Krasnojon, Sergey Cheporov et al. · Clinical Breast Cancer · 2012 · 122 citations

Medicine, Oncology, Pharmacology +11